Foresite Capital Management II’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Foresite Capital Management II’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-83,211	Closed	-$1.35M	–	15
2016 Q2	$1.35M	Sell	83,211 -36,570	-31%	-$616K	0.92%	13
2016 Q1	$1.69M	Buy	119,781 +64,002	+115%	+$865K	0.83%	18
2015 Q4	$951K	Sell	55,779 -21,022	-27%	-$409K	0.32%	24
2015 Q3	$1.59M	Buy	76,801 +2,416	+3%	+$49.6K	0.48%	26
2015 Q2	$1.14M	Buy	+74,385	New	+$1.05M	0.4%	19

Other funds holding NDRM

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Foresite Capital Management II's NDRM Position: Q3 2016 in Review

Foresite Capital Management II sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2016, closing a stake of 83,211 shares — an estimated $1.35M sold.

Foresite Capital Management II first reported a position in NDRM in Q2 2015 and held it in 5 quarters. The position peaked at $1.69M in Q1 2016. 50 funds tracked by Wall St. Rank hold NDRM as of Q3 2016.

Foresite Capital Management II reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2016 after selling out during the quarter.
Foresite Capital Management II sold 83,211 NeuroDerm Ltd. Ordinary Shares shares in Q3 2016, an estimated $1.35M.
Foresite Capital Management II first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2015 and held it in 5 quarters.
Foresite Capital Management II's NeuroDerm Ltd. Ordinary Shares position peaked at $1.69M in Q1 2016.
50 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2016.

Based on Foresite Capital Management II's 13F filing for Q3 2016, filed 14 Nov 2016.